Welcome to our dedicated page for Evo Acquisition news (Ticker: EVOJ), a resource for investors and traders seeking the latest updates and insights on Evo Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evo Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evo Acquisition's position in the market.
Evo Acquisition Corp. (NASDAQ: EVOJU) announced the successful closing of its upsized IPO, issuing 12,500,500 units at $10.00 each, totaling gross proceeds of $125,005,000. The IPO included a full exercise of the underwriters’ over-allotment option. Each unit comprises one share of Class A common stock and a half warrant, with the whole warrant exercisable at $11.50. The offering began trading on February 9, 2021, and the proceeds will be placed in a trust account to facilitate a potential business combination, particularly targeting tech and financial sectors.
Evo Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 10,870,000 units at $10.00 per unit, set to trade on Nasdaq under the symbol EVOJU starting February 9, 2021. Each unit includes one share of Class A common stock and a half redeemable warrant. The anticipated closing date for the offering is February 11, 2021, subject to customary conditions. The company, aimed at potential mergers in technology and financial sectors, has granted underwriters a 45-day option for an additional 1,630,500 units to cover over-allotments.